BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, January 10, 2026
See today's BioWorld Asia
Home
» Yuhan-Sorrento’s cancer-focused Immuneoncia targets Kosdaq IPO
To read the full story,
subscribe
or
sign in
.
Yuhan-Sorrento’s cancer-focused Immuneoncia targets Kosdaq IPO
April 23, 2024
By
Marian (YoonJee) Chu
Immuneoncia Therapeutics Inc., a joint venture between South Korea’s Yuhan Corp. and San Diego-based Sorrento Therapeutics Inc., is looking to list on the Korea Exchange, having recently passed local technology evaluation.
BioWorld Asia
Financings
Cancer
Immuno-oncology
IPO
Asia-Pacific